Welcome to Managing AML, I am Dr. Hetty Carraway. Today, I would like to discuss whether I re-test patients at relapse who were found to have an IDH mutation at diagnosis. I believe that, for many of our patients that do relapse with their AML, it is probably important for us to have a better understanding of clonal evolution, and it is reasonable to re-test patients to see if their IDH mutation is still present at relapse. For this reason, I would favor re-testing patients at the time of relapse to clarify whether or not the IDH mutation is still present, and to ensure that if we were to proceed with enasidenib as a single agent in that setting, that it would actually be a lesion that is present on the leukemia at that time. Thank you for viewing this activity.